Aptevo reports 93% clinical benefit rate with mipletamig triplet in TP53-mutated AML
Aptevo Therapeutics reported a 93% clinical benefit rate in evaluable TP53-mutated AML patients treated with its mipletamig triplet, nearly double published venetoclax outcomes, showcasing potential for a difficult-to-treat population.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day